ReviewDiagnostics (Basel, Switzerland)2026
Multimodal Magnetic Resonance Imaging in Diabetic Kidney Disease: From Pathophysiological Insights to Clinical Applications.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic kidney disease (DKD) is the leading cause of end-stage renal disease. Conventional clinical markers of renal function lack sufficient sensitivity for early diagnosis, whereas renal biopsy is unsuitable for routine monitoring because of its invasiveness.
objectiveThis narrative review aimed to evaluate recent advances in novel, non-invasive multimodal magnetic resonance imaging (MRI) biomarkers for the assessment of renal pathological alterations in DKD. RECENT
findingsRecent studies have demonstrated that multimodal MRI can non-invasively characterize several key pathological features of DKD, including renal hypoxia, microvascular dysfunction, ectopic fat deposition, and interstitial fibrosis. Furthermore, emerging evidence suggests that these imaging biomarkers may enhance risk stratification, monitor disease progression, and assess treatment efficacy, particularly in the presence of comorbidities and the advent of emerging therapies.
conclusionsMultimodal MRI shows considerable promise in translating advanced imaging biomarkers into clinical practice, facilitating the personalized management of DKD. However, future research must focus on establishing standardized imaging acquisition and analytical protocols, conducting prospective cohort studies to validate the association between imaging biomarkers and hard clinical endpoints, integrating artificial intelligence for automated analysis, and developing molecular imaging probes targeted at early disease pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.